PENTIXAPHARM HOLDING N AG (PTP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PENTIXAPHARM HOLDING N AG (PTP) has a cash flow conversion efficiency ratio of -0.090x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.57 Million ≈ $-3.01 Million USD) by net assets (€28.47 Million ≈ $33.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PTP market cap for the company's overall valuation and market capitalisation.
PENTIXAPHARM HOLDING N AG - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PENTIXAPHARM HOLDING N AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PENTIXAPHARM HOLDING N AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PENTIXAPHARM HOLDING N AG ranked by their cash flow conversion efficiency. See PTP operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Health In Tech, Inc. Class A Common Stock
NASDAQ:HIT
|
-0.154x |
|
Werewolf Therapeutics Inc
NASDAQ:HOWL
|
0.407x |
|
Pancontinental Energy NL
AU:PCL
|
-0.064x |
|
Ado Optronics
TWO:3516
|
0.009x |
|
Enzymatica publ AB
ST:ENZY
|
-0.085x |
|
Shuang-Bang Industrial
TWO:6506
|
0.035x |
|
Toro Energy Ltd
AU:TOE
|
-0.245x |
|
Vishnu Prakash R Punglia Limited
NSE:VPRPL
|
0.089x |
Annual Cash Flow Conversion Efficiency for PENTIXAPHARM HOLDING N AG (2021–2025)
The table below shows the annual cash flow conversion efficiency of PENTIXAPHARM HOLDING N AG from 2021 to 2025. View latest PENTIXAPHARM HOLDING N AG stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €35.07 Million ≈ $41.00 Million |
€-17.97 Million ≈ $-21.01 Million |
-0.512x | -485.10% |
| 2024-12-31 | €49.41 Million ≈ $57.77 Million |
€-4.33 Million ≈ $-5.06 Million |
-0.088x | -299.63% |
| 2023-12-31 | €48.48 Million ≈ $56.68 Million |
€2.13 Million ≈ $2.49 Million |
0.044x | +176.78% |
| 2022-12-31 | €38.47 Million ≈ $44.97 Million |
€-2.20 Million ≈ $-2.57 Million |
-0.057x | -16.04% |
| 2021-12-31 | €27.88 Million ≈ $32.60 Million |
€-1.37 Million ≈ $-1.61 Million |
-0.049x | -- |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more